By Professor Michelle Haber

Journal articles

Putra V; Hulme AJ; Tee AE; Sun JQJ; Atmadibrata B; Ho N; Chen J; Gao J; Norris MD; Haber M; Kavallaris M; Henderson MJ; McCarroll J; Trahair T; Liu T; Liu PY, 2021, 'The RNA-helicase DDX21 upregulates CEP55 expression and promotes neuroblastoma', Molecular Oncology, 15, pp. 1162 - 1179, http://dx.doi.org/10.1002/1878-0261.12906

Grohmann C; Walker F; Devlin M; Luo MX; Chüeh AC; Doherty J; Vaillant F; Ho GY; Wakefield MJ; Weeden CE; Kamili A; Murray J; Po’uha ST; Weinstock J; Kane SR; Faux MC; Broekhuizen E; Zheng Y; Shield-Artin K; Kershaw NJ; Tan CW; Witchard HM; Ebert G; Charman SA; Street I; Kavallaris M; Haber M; Fletcher JI; Asselin-Labat ML; Scott CL; Visvader JE; Lindeman GJ; Watson KG; Burgess AW; Lessene G, 2021, 'Preclinical small molecule WEHI-7326 overcomes drug resistance and elicits response in patient-derived xenograft models of human treatment-refractory tumors', Cell Death and Disease, 12, pp. 268, http://dx.doi.org/10.1038/s41419-020-03269-0

Chen J; Nelson C; Wong M; Tee AE; Liu PY; La T; Fletcher JI; Kamili A; Mayoh C; Bartenhagen C; Trahair TN; Xu N; Jayatilleke N; Wong M; Peng H; Atmadibrata B; Cheung BB; Lan Q; Bryan TM; Mestdagh P; Vandesompele J; Combaret V; Boeva V; Wang JY; Janoueix-Lerosey I; Cowley MJ; MacKenzie KL; Dolnikov A; Li J; Polly P; Marshall GM; Reddel RR; Norris MD; Haber M; Fischer M; Zhang XD; Pickett HA; Liu T, 2021, 'Targeted therapy of TERT-rearranged neuroblastoma with BET bromodomain inhibitor and proteasome inhibitor combination therapy', Clinical Cancer Research, 27, pp. 1438 - 1451, http://dx.doi.org/10.1158/1078-0432.CCR-20-3044

Xu N; Tse B; Yang L; Tang TC; Haber M; Micklethwaite K; Dolnikov A, 2021, 'Priming Leukemia with 5-Azacytidine Enhances CAR T Cell Therapy', IMMUNOTARGETS AND THERAPY, 10, pp. 123 - 140, http://dx.doi.org/10.2147/ITT.S296161

Xie J; Kumar A; Dolman MEM; Mayoh C; Khuong-Quang DA; Cadiz R; Wong-Erasmus M; Mould EVA; Grebert-Wade D; Barahona P; Kamili A; Tsoli M; Failes TW; Chow SO; Bhatia K; Marshall GM; Ziegler DS; Haber M; Lock RB; Tyrrell V; Lau L; Athanasatos P; Gifford AJ; Arndt G, 2021, 'The important role of routine cytopathology in pediatric precision oncology', Cancer Cytopathology, 129, pp. 805 - 818, http://dx.doi.org/10.1002/cncy.22448

Subhash VV; Huang L; Kamili A; Wong M; Chen D; Venn NC; Atkinson C; Mayoh C; Venkat P; Tyrrell V; Marshall GM; Cowley MJ; Ekert PG; Norris MD; Haber M; Henderson MJ; Sutton R; Fletcher JI; Trahair TN; Vijayasubhash V, 2021, 'Whole-genome sequencing facilitates patient-specific quantitative PCR-based minimal residual disease monitoring in acute lymphoblastic leukaemia, neuroblastoma and Ewing sarcoma', British Journal of Cancer, 126, pp. 482 - 491, http://dx.doi.org/10.1038/s41416-021-01538-z

Ehteda A; Simon S; Franshaw L; Giorgi FM; Liu J; Hayden E; Rouaen J; Pang CNI; Pandher R; Mayoh C; Tang Y; Khan A; Ung C; Kankean A; Lehmann R; Shen S; Gopalakrishnan A; Trebilcock P; Gurova K; Gudkov A; Norris MD; Haber M; Vittorio O; Tsoli M; Ziegler DS, 2021, 'HGG-09. TARGETING FACILITATES CHROMATIN TRANSCRIPTION (FACT) AS A NOVEL STRATEGY THAT ENHANCES RESPONSE TO HISTONE DEACETYLASE (HDAC) INHIBITION IN DIPG', Neuro-oncology, 23, pp. i18 - i19

Khan A; Gamble L; Upton D; Yu D; Pandher R; Mayoh C; Burns MR; Norris MD; Haber M; Tsoli M; Ziegler DS, 2021, 'RARE-02. POLYAMINE PATHWAY INHIBITION IS A POTENT NOVEL THERAPEUTIC STRATEGY AGAINST DIFFUSE INTRINSIC PONTINE GLIOMA', Neuro-oncology, 23, pp. i40 - i41

Khuong-Quang DA; Brown LM; Wong M; Mayoh C; Sexton-Oates A; Kumar A; Pinese M; Nagabushan S; Lau L; Ludlow LE; Gifford AJ; Rodriguez M; Desai J; Fox SB; Haber M; Ziegler DS; Hansford JR; Marshall GM; Cowley MJ; Ekert PG; Wong-Erasmus M, 2020, 'Recurrent SPECC1L–NTRK fusions in pediatric sarcoma and brain tumors', Cold Spring Harbor Molecular Case Studies, 6, pp. mcs.a005710, http://dx.doi.org/10.1101/MCS.A005710

Sia KCS; Zhong L; Mayoh C; Norris MD; Haber M; Marshall GM; Raftery MJ; Lock RB, 2020, 'Targeting TSLP-induced tyrosine kinase signaling pathways in CRLF2-Rearranged Ph-like ALL', Molecular Cancer Research, 18, pp. 1767 - 1776, http://dx.doi.org/10.1158/1541-7786.MCR-19-1098

Ferrucci F; Ciaccio R; Monticelli S; Pigini P; Di Giacomo S; Purgato S; Erriquez D; Bernardoni R; Norris MD; Haber M; Milazzo G; Perini G, 2020, 'Corrigendum to: “MAX to MYCN intracellular ratio drives the aggressive phenotype and clinical outcome of high risk neuroblastoma” [Biochim. Biophys. Acta, Gene Regul. Mech. 1861 (2018) 235–245] (BBA - Gene Regulatory Mechanisms (2018) 1861(3) (235–245), (S1874939917302894), (10.1016/j.bbagrm.2018.01.007))', Biochimica et Biophysica Acta - Gene Regulatory Mechanisms, 1863, http://dx.doi.org/10.1016/j.bbagrm.2020.194645

Wong M; Mayoh C; Lau LMS; Khuong-Quang DA; Pinese M; Kumar A; Barahona P; Wilkie EE; Sullivan P; Bowen-James R; Syed M; Martincorena I; Abascal F; Sherstyuk A; Bolanos NA; Baber J; Priestley P; Dolman MEM; Fleuren EDG; Gauthier ME; Mould EVA; Gayevskiy V; Gifford AJ; Grebert-Wade D; Strong PA; Manouvrier E; Warby M; Thomas DM; Kirk J; Tucker K; O’Brien T; Alvaro F; McCowage GB; Dalla-Pozza L; Gottardo NG; Tapp H; Wood P; Khaw SL; Hansford JR; Moore AS; Norris MD; Trahair TN; Lock RB; Tyrrell V; Haber M; Marshall GM; Ziegler DS; Ekert PG; Cowley MJ; O'Brien T; Wong-Erasmus M, 2020, 'Whole genome, transcriptome and methylome profiling enhances actionable target discovery in high-risk pediatric cancer', Nature Medicine, 26, pp. 1742 - 1753, http://dx.doi.org/10.1038/s41591-020-1072-4

Jung M; Gao J; Cheung L; Bongers A; Somers K; Clifton M; Ramsay EE; Russell AJ; Valli E; Gifford AJ; George J; Kennedy CJ; Wakefield MJ; Topp M; Ho GY; Scott CL; Bowtell DD; deFazio A; Norris MD; Haber M; Henderson MJ, 2020, 'ABCC4/MRP4 contributes to the aggressiveness of Myc-associated epithelial ovarian cancer', International Journal of Cancer, 147, pp. 2225 - 2238, http://dx.doi.org/10.1002/ijc.33005

Hawkins C; Pfister S; Jones DTW; Shah NN; Gilbertson RJ; Sweet-Cordero EA; Dyer MA; Mossé YP; Haber M; DuBois SG, 2020, 'Advances and Challenges in Pediatric and Childhood Cancers', Cancer Cell, 38, pp. 429 - 432, http://dx.doi.org/10.1016/j.ccell.2020.09.013

Voli F; Valli E; Lerra L; Kimpton K; Saletta F; Giorgi FM; Mercatelli D; Rouaen JRC; Shen S; Murray JE; Ahmed-Cox A; Cirillo G; Mayoh C; Beavis PA; Haber M; Trapani JA; Kavallaris M; Vittorio O, 2020, 'Intratumoral copper modulates PD-L1 expression and influences tumor immune evasion', Cancer Research, 80, pp. 4129 - 4144, http://dx.doi.org/10.1158/0008-5472.CAN-20-0471

Gao J; Jung MS; Mayoh C; Venkat P; Hannan KM; Fletcher JI; Kamili A; Gifford AJ; Kusnadi EP; Pearson RB; Hannan RD; Haber M; Norris MD; Somers K; Henderson MJ, 2020, 'Suppression of ABCE1-mediated mRNA translation limits N-MYC-driven cancer progression', Cancer Research, 80, pp. 3706 - 3718, http://dx.doi.org/10.1158/0008-5472.CAN-19-3914

Salik B; Yi H; Hassan N; Santiappillai N; Vick B; Connerty P; Duly A; Trahair T; Woo AJ; Beck D; Liu T; Spiekermann K; Jeremias I; Wang J; Kavallaris M; Haber M; Norris MD; Liebermann DA; D'Andrea RJ; Murriel C; Wang JY, 2020, 'Targeting RSPO3-LGR4 Signaling for Leukemia Stem Cell Eradication in Acute Myeloid Leukemia', Cancer Cell, 38, pp. 263 - 278.e6, http://dx.doi.org/10.1016/j.ccell.2020.05.014

Terry RL; Meyran D; Ziegler DS; Haber M; Ekert PG; Trapani JA; Neeson PJ, 2020, 'Immune profiling of pediatric solid tumors', Journal of Clinical Investigation, 130, pp. 3391 - 3402, http://dx.doi.org/10.1172/JCI137181

Korotchkina L; Kazyulkin D; Komarov PG; Polinsky A; Andrianova EL; Joshi S; Gupta M; Vujcic S; Kononov E; Toshkov I; Tian Y; Krasnov P; Chernov MV; Veith J; Antoch MP; Middlemiss S; Somers K; Lock RB; Norris MD; Henderson MJ; Haber M; Chernova OB; Gudkov AV, 2020, 'OT-82, a novel anticancer drug candidate that targets the strong dependence of hematological malignancies on NAD biosynthesis', Leukemia, 34, pp. 1828 - 1839, http://dx.doi.org/10.1038/s41375-019-0692-5

Somers K; Evans K; Cheung L; Karsa M; Pritchard T; Kosciolek A; Bongers A; El-Ayoubi A; Forgham H; Middlemiss S; Mayoh C; Jones L; Gupta M; Kees UR; Chernova O; Korotchkina L; Gudkov AV; Erickson SW; Teicher B; Smith MA; Norris MD; Haber M; Lock RB; Henderson MJ, 2020, 'Effective targeting of NAMPT in patient-derived xenograft models of high-risk pediatric acute lymphoblastic leukemia', Leukemia, 34, pp. 1524 - 1539, http://dx.doi.org/10.1038/s41375-019-0683-6

Khan A; Valli E; Lam H; Scott DA; Murray J; Hanssen KM; Eden G; Gamble LD; Pandher R; Flemming CL; Allan S; Osterman AL; Haber M; Norris MD; Fletcher JI; Yu DMT, 2020, 'Targeting metabolic activity in high-risk neuroblastoma through Monocarboxylate Transporter 1 (MCT1) inhibition', Oncogene, 39, pp. 3555 - 3570, http://dx.doi.org/10.1038/s41388-020-1235-2

Xie J; Span M; van Maarseveen E; Langenhorst J; Boddy AV; Sia KCS; Sutton R; Venn N; Punt AM; Tyrrell V; Haber M; Trahair T; Lau L; Marshall GM; Lock RB, 2020, 'Optimization of a clofarabine-based drug combination regimen for the preclinical evaluation of pediatric acute lymphoblastic leukemia', Pediatric Blood and Cancer, 67, pp. e28133, http://dx.doi.org/10.1002/pbc.28133

Huynh T; Murray J; Flemming CL; Kamili A; Hofmann U; Cheung L; Roundhill EA; Yu DMT; Webber HT; Schwab M; Henderson MJ; Haber M; Norris MD; Fletcher JI, 2020, 'CCI52 sensitizes tumors to 6-mercaptopurine and inhibits MYCN-amplified tumor growth', Biochemical Pharmacology, 172, pp. 113770, http://dx.doi.org/10.1016/j.bcp.2019.113770

Kamili A; Gifford AJ; Li N; Mayoh C; Chow S-O; Failes TW; Eden GL; Cadiz R; Xie J; Lukeis RE; Norris MD; Haber M; McCowage GB; Arndt GM; Trahair TN; Fletcher JI, 2020, 'Accelerating development of high-risk neuroblastoma patient-derived xenograft models for preclinical testing and personalised therapy', British Journal of Cancer, 122, pp. 680 - 691, http://dx.doi.org/10.1038/s41416-019-0682-4

Khan A; Gamble L; Upton D; Yu D; Ehteda A; Pandher R; Mayoh C; Burns M; Norris M; Haber M; Tsoli M; Ziegler D, 2020, 'DIPG-15. POLYAMINE PATHWAY INHIBITION IS A POTENT NOVEL THERAPEUTIC STRATEGY AGAINST DIFFUSE INTRINSIC PONTINE GLIOMA', Neuro-oncology, 22, pp. iii289 - iii290

Khan A; Gamble L; Pandher R; Burns MR; Mussai F; Norris M; Haber M; Tsoli M; Ziegler DS, 2020, 'DIPG-16. COMBINATION OF ARGININE DEPLETION AND POLYAMINE INHIBITION AS AN ANTICANCER STRATEGY FOR DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG)', Neuro-oncology, 22, pp. iii290 - iii290

Ehteda A; Franshaw L; Liu J; Joshi S; Simon S; Pang CNI; Giorgi F; Pandher R; Ung C; Tolhurst O; Mayoh C; Khan A; Hayden E; Gopalakrishnan A; Trebilcock P; Upton D; Lehmann R; George S; Vittorio O; Tsoli M; Gurova K; Gudkov AG; Norris MD; Haber M; Ziegler DS, 2020, 'DIPG-27. TARGETING FACILITATES CHROMATIN TRANSCRIPTION (FACT) AS A NOVEL STRATEGY FOR DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG) THAT ENHANCES RESPONSE TO HISTONE DEACETYLASE (HDAC) INHIBITION', Neuro-oncology, 22, pp. iii292 - iii292

Wong M; Sun Y; Xi Z; Milazzo G; Poulos RC; Bartenhagen C; Bell JL; Mayoh C; Ho N; Tee AE; Chen X; Li Y; Ciaccio R; Liu PY; Jiang CC; Lan Q; Jayatilleke N; Cheung BB; Haber M; Norris MD; Zhang XD; Marshall GM; Wang JY; Hüttelmaier S; Fischer M; Wong JWH; Xu H; Perini G; Dong Q; George RE; Liu T, 2019, 'JMJD6 is a tumorigenic factor and therapeutic target in neuroblastoma', Nature Communications, 10, pp. 3319, http://dx.doi.org/10.1038/s41467-019-11132-w

Liu PY; Tee AE; Milazzo G; Hannan KM; Maag J; Mondal S; Atmadibrata B; Bartonicek N; Peng H; Ho N; Mayoh C; Ciaccio R; Sun Y; Henderson MJ; Gao J; Everaert C; Hulme AJ; Wong M; Lan Q; Cheung BB; Shi L; Wang JY; Simon T; Fischer M; Zhang XD; Marshall GM; Norris MD; Haber M; Vandesompele J; Li J; Mestdagh P; Hannan RD; Dinger ME; Perini G; Liu T, 2019, 'The long noncoding RNA lncNB1 promotes tumorigenesis by interacting with ribosomal protein RPL35', Nature Communications, 10, pp. 5026, http://dx.doi.org/10.1038/s41467-019-12971-3

Rokita JL; Rathi KS; Cardenas MF; Upton KA; Jayaseelan J; Cross KL; Pfeil J; Egolf LE; Way GP; Farrel A; Kendsersky NM; Patel K; Gaonkar KS; Modi A; Berko ER; Lopez G; Vaksman Z; Mayoh C; Nance J; McCoy K; Haber M; Evans K; McCalmont H; Bendak K; Böhm JW; Marshall GM; Tyrrell V; Kalletla K; Braun FK; Qi L; Du Y; Zhang H; Lindsay HB; Zhao S; Shu J; Baxter P; Morton C; Kurmashev D; Zheng S; Chen Y; Bowen J; Bryan AC; Leraas KM; Coppens SE; Doddapaneni HV; Momin Z; Zhang W; Sacks GI; Hart LS; Krytska K; Mosse YP; Gatto GJ; Sanchez Y; Greene CS; Diskin SJ; Vaske OM; Haussler D; Gastier-Foster JM; Kolb EA; Gorlick R; Li XN; Reynolds CP; Kurmasheva RT; Houghton PJ; Smith MA; Lock RB; Raman P; Wheeler DA; Maris JM, 2019, 'Genomic Profiling of Childhood Tumor Patient-Derived Xenograft Models to Enable Rational Clinical Trial Design', Cell Reports, 29, pp. 1675 - 1689.e9, http://dx.doi.org/10.1016/j.celrep.2019.09.071

Koach J; Holien JK; Massudi H; Carter DR; Ciampa OC; Herath M; Lim T; Seneviratne JA; Milazzo G; Murray JE; McCarroll JA; Liu B; Mayoh C; Keenan B; Stevenson BW; Gorman MA; Bell JL; Doughty L; Hüttelmaier S; Oberthuer A; Fischer M; Gifford AJ; Liu T; Zhang X; Zhu S; Gustafson WC; Haber M; Norris MD; Fletcher JI; Perini G; Parker MW; Cheung BB; Marshall GM, 2019, 'Drugging MYCN oncogenic signaling through the MYCN-PA2G4 binding interface', Cancer Research, 79, pp. 5652 - 5667, http://dx.doi.org/10.1158/0008-5472.CAN-19-1112

Gana CC; Hanssen KM; Yu DMT; Flemming CL; Wheatley MS; Conseil G; Cole SPC; Norris MD; Haber M; Fletcher JI, 2019, 'MRP1 modulators synergize with buthionine sulfoximine to exploit collateral sensitivity and selectively kill MRP1-expressing cancer cells', Biochemical Pharmacology, 168, pp. 237 - 248, http://dx.doi.org/10.1016/j.bcp.2019.07.009

Jones DTW; Banito A; Grünewald TGP; Haber M; Jäger N; Kool M; Milde T; Molenaar JJ; Nabbi A; Pugh TJ; Schleiermacher G; Smith MA; Westermann F; Pfister SM, 2019, 'Molecular characteristics and therapeutic vulnerabilities across paediatric solid tumours', Nature Reviews Cancer, 19, pp. 420 - 438, http://dx.doi.org/10.1038/s41568-019-0169-x

Gonzales-Aloy E; Connerty P; Salik B; Liu B; Woo AJ; Haber M; Norris MD; Wang J; Wang JY, 2019, 'MiR-101 suppresses the development of MLL-rearranged acute myeloid leukemia', Haematologica, 104, pp. e296 - e299, http://dx.doi.org/10.3324/haematol.2018.209437

Lynch JR; Salik B; Connerty P; Vick B; Leung H; Pijning A; Jeremias I; Spiekermann K; Trahair T; Liu T; Haber M; Norris MD; Woo AJ; Hogg P; Wang J; Wang JY, 2019, 'JMJD1C-mediated metabolic dysregulation contributes to HOXA9-dependent leukemogenesis', Leukemia, 33, pp. 1400 - 1410, http://dx.doi.org/10.1038/s41375-018-0354-z

Somers K; Wen VW; Middlemiss SMC; Osborne B; Forgham H; Jung MS; Karsa M; Clifton M; Bongers A; Gao J; Mayoh C; Raoufi-Rad N; Kusnadi EP; Hannan KM; Scott DA; Kwek A; Liu B; Flemming C; Chudakova DA; Pandher R; Failes TW; Lim J; Angeli A; Osterman AL; Imamura T; Kees UR; Supuran CT; Pearson RB; Hannan RD; Davis TP; McCarroll J; Kavallaris M; Turner N; Gudkov AV; Haber M; Norris MD; Henderson MJ, 2019, 'A novel small molecule that kills a subset of MLL-rearranged leukemia cells by inducing mitochondrial dysfunction', Oncogene, 38, pp. 3824 - 3842, http://dx.doi.org/10.1038/s41388-018-0666-5

Fultang L; Gamble LD; Gneo L; Berry AM; Egan SA; De Bie F; Yogev O; Eden GL; Booth S; Brownhill S; Vardon A; McConville CM; Cheng PN; Norris MD; Etchevers HC; Murray J; Ziegler DS; Chesler L; Schmidt R; Burchill SA; Haber M; De Santo C; Mussai F, 2019, 'Macrophage-derived IL1B and TNFa regulate arginine metabolism in neuroblastoma', Cancer Research, 79, pp. 611 - 624, http://dx.doi.org/10.1158/0008-5472.CAN-18-2139

Dorstyn L; Hackett-Jones E; Nikolic A; Norris MD; Lim Y; Toubia J; Haber M; Kumar S, 2019, 'Transcriptome profiling of caspase-2 deficient EμMyc and Th-MYCN mouse tumors identifies distinct putative roles for caspase-2 in neuronal differentiation and immune signaling', Cell Death and Disease, 10, pp. 56, http://dx.doi.org/10.1038/s41419-018-1296-0

Gamble LD; Purgato S; Murray J; Xiao L; Yu DMT; Hanssen KM; Giorgi FM; Carter DR; Gifford AJ; Valli E; Milazzo G; Kamili A; Mayoh C; Liu B; Eden G; Sarraf S; Allan S; Giacomo SD; Flemming CL; Russell AJ; Cheung BB; Oberthuer A; London WB; Fischer M; Trahair TN; Fletcher JI; Marshall GM; Ziegler DS; Hogarty MD; Burns MR; Perini G; Norris MD; Haber M, 2019, 'Inhibition of polyamine synthesis and uptake reduces tumor progression and prolongs survival in mouse models of neuroblastoma', Science Translational Medicine, 11, http://dx.doi.org/10.1126/scitranslmed.aau1099

Somers K; Kosciolek A; Bongers A; El-Ayoubi A; Karsa M; Mayoh C; Wadham C; Middlemiss S; Neznanov N; Kees UR; Lock RB; Gudkov A; Sutton R; Gurova K; Haber M; Norris MD; Henderson MJ; Bongers A, 2019, 'Potent antileukemic activity of curaxin CBL0137 against MLL-rearranged leukemia', International Journal of Cancer, 146, pp. 1902 - 1916, http://dx.doi.org/10.1002/ijc.32582

Tsoli M; Wadham C; Pinese M; Failes T; Joshi S; Mould E; Yin JX; Gayevskiy V; Kumar A; Kaplan W; Ekert PG; Saletta F; Franshaw L; Liu J; Gifford A; Weber MA; Rodriguez M; Cohn RJ; Arndt G; Tyrrell V; Haber M; Trahair T; Marshall GM; McDonald K; Cowley MJ; Ziegler DS; Arndt G, 2018, 'Integration of genomics, high throughput drug screening, and personalized xenograft models as a novel precision medicine paradigm for high risk pediatric cancer', Cancer Biology and Therapy, 19, pp. 1078 - 1087, http://dx.doi.org/10.1080/15384047.2018.1491498

Jung M; Russell A; Kennedy C; Gifford A; Mallitt K-A; Henderson M; Haber M; Norris M, 2018, 'Clinical Importance of Myc Family Oncogene Aberrations in Epithelial Ovarian Cancer', JNCI: Cancer Spectrum, 2, pp. pky047, http://dx.doi.org/10.1093/jncics/pky047

Ziegler DS; Wong M; Mayoh C; Kumar A; Tsoli M; Mould E; Tyrrell V; Khuong-Quang DA; Pinese M; Gayevskiy V; Cohn RJ; Lau LMS; Reynolds M; Cox MC; Gifford A; Rodriguez M; Cowley MJ; Ekert PG; Marshall GM; Haber M; Wong-Erasmus M, 2018, 'Brief Report: Potent clinical and radiological response to larotrectinib in TRK fusion-driven high-grade glioma', British Journal of Cancer, 119, pp. 693 - 696, http://dx.doi.org/10.1038/s41416-018-0251-2

Ooi CY; Carter DR; Liu B; Mayoh C; Beckers A; Lalwani A; Nagy Z; De Brouwer S; Decaesteker B; Hung TT; Norris MD; Haber M; Liu T; De Preter K; Speleman F; Cheung BB; Marshall GM, 2018, 'Network modeling of microRNA-mRNA interactions in neuroblastoma tumorigenesis identifies miR-204 as a direct inhibitor of MYCN', Cancer Research, 78, pp. 3122 - 3134, http://dx.doi.org/10.1158/0008-5472.CAN-17-3034

Fletcher JI; Ziegler DS; Trahair TN; Marshall GM; Haber M; Norris MD, 2018, 'Too many targets, not enough patients: Rethinking neuroblastoma clinical trials', Nature Reviews Cancer, 18, pp. 389 - 400, http://dx.doi.org/10.1038/s41568-018-0003-x

Marachelian A; Hogarty MD; Flynn A; Liu K; Gerner EW; Bruckheimer E; Shamirian A; Hasenauer C; Norris M; Haber M; Groshen SG; Ziegler DS; Matthay KK, 2018, 'NANT 2012-01: Phase 1 study of DFMO and celecoxib with cyclophosphamide and topotecan for relapsed or refractory high-risk neuroblastoma.', JOURNAL OF CLINICAL ONCOLOGY, 36, http://dx.doi.org/10.1200/JCO.2018.36.15_suppl.10558

Ferrucci F; Ciaccio R; Monticelli S; Pigini P; di Giacomo S; Purgato S; Erriquez D; Bernardoni R; Norris M; Haber M; Milazzo G; Perini G, 2018, 'MAX to MYCN intracellular ratio drives the aggressive phenotype and clinical outcome of high risk neuroblastoma', Biochimica et Biophysica Acta - Gene Regulatory Mechanisms, 1861, pp. 235 - 245, http://dx.doi.org/10.1016/j.bbagrm.2018.01.007

Sutton R; Venn NC; Law T; Boer JM; Trahair TN; Ng A; Den Boer ML; Dissanayake A; Giles JE; Dalzell P; Mayoh C; Barbaric D; Revesz T; Alvaro F; Pieters R; Haber M; Norris MD; Schrappe M; Dalla Pozza L; Marshall GM, 2018, 'A risk score including microdeletions improves relapse prediction for standard and medium risk precursor B-cell acute lymphoblastic leukaemia in children', British Journal of Haematology, 180, pp. 550 - 562, http://dx.doi.org/10.1111/bjh.15056

Khan A; Gamble L; Yu D; Joshi S; Franshaw L; Burns M; Norris M; Haber M; Tsoli M; Ziegler D, 2018, 'DIPG-01. TARGETING THE POLYAMINE PATHWAY AS A NOVEL THERAPEUTIC TREATMENT AGAINST DIFFUSE INTRINSIC PONTINE GLIOMA', Neuro-oncology, 20, pp. i49 - i49

Somers K; Evans K; Cheung L; Korotchkina L; Chernova O; Gudkov A; Norris M; Haber M; Lock R; Henderson M, 2018, 'PO-028 Effective targeting of NAD+biosynthesis in patient-derived xenograft models of high-risk paediatric acute lymphoblastic leukaemia', ESMO Open, 3, pp. A238 - A238, http://dx.doi.org/10.1136/esmoopen-2018-eacr25.563

Back to profile page